Abstract: Chimeric antigen receptor T cells （CART） therapy is a new method of tumor immunotherapy. The complete response rate of CART cell therapy for B cell acute lymphoblastic leukemia （BALL） is as high as 90％. However， there are some problems of CART cell therapy in the treatment of blood tumor， such as offtarget activity， toxic side effect， short duration of the body and high recurrence rate. In addition， the safety and efficacy of CART cells in the treatment of solid tumors have been confirmed， but the efficacy remains to be improved. In this paper， the research progression of CART cell therapy in recent years and the urgent problems in this field are analyzed and prospected.

Key words: Tumor, Chimeric antigen receptor T cells （CART）, Tumor immunotherapy